Your session is about to expire
← Back to Search
Monoclonal Antibodies
Depemokimab for Asthma
Phase 1
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests Depemokimab given by a small syringe or autoinjector in healthy people to see how the body handles it, its safety, and if it causes any immune responses.
Who is the study for?
Healthy adults who weigh at least 50 kg with a BMI of 19-30 can join. They must have no significant allergies, especially to monoclonal antibodies or biologics, and no history of severe drug allergies or substance abuse. Women able to get pregnant should use effective birth control.
What is being tested?
The trial is testing Depemokimab delivered through two different devices: a Safety Syringe Device (SSD) and an autoinjector. It aims to compare how the body absorbs the drug, its safety, tolerability, and potential for immune response.
What are the potential side effects?
Possible side effects are not detailed but may include reactions typical for monoclonal antibody treatments such as injection site reactions, allergic responses, fatigue, headache, or flu-like symptoms.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Participants receiving depemokimab via an autoinjectorExperimental Treatment1 Intervention
Group II: Participants receiving depemokimab via a SSDExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Depemokimab
2022
Completed Phase 1
~140
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
PPD DEVELOPMENT, LPIndustry Sponsor
158 Previous Clinical Trials
35,909 Total Patients Enrolled
4 Trials studying Asthma
1,521 Patients Enrolled for Asthma
GlaxoSmithKlineLead Sponsor
4,802 Previous Clinical Trials
8,377,862 Total Patients Enrolled
301 Trials studying Asthma
500,492 Patients Enrolled for Asthma
PPDIndustry Sponsor
161 Previous Clinical Trials
36,251 Total Patients Enrolled
4 Trials studying Asthma
1,521 Patients Enrolled for Asthma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had serious allergies or intolerances to certain medications or biological treatments in the past.You currently have or recently had a contagious illness.You have any health condition that could affect how your body absorbs, processes, or eliminates medications, or that could interfere with the study results.
Research Study Groups:
This trial has the following groups:- Group 1: Participants receiving depemokimab via a SSD
- Group 2: Participants receiving depemokimab via an autoinjector
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Asthma Patient Testimony for trial: Trial Name: NCT05602025 — Phase 1
Share this study with friends
Copy Link
Messenger